Andrew MacIsaac

Andrew MacIsaac is the CEO of Applied Pharmaceutical Innovation (API), a non-profit laboratory and manufacturing facility in Edmonton. He is involved in the development of Vimy Pharmaceuticals' generic semaglutide, emphasizing the importance of domestic drug production in Canada.